


ORION-10

#AHA19



AMERICAN
COLLEGE *of*
CARDIOLOGY®

Trial Description: Patients with ASCVD on maximum tolerated statin therapy were randomized to inclisiran 300 mg injection daily vs. placebo. Study drug injection was administered on day 1, day 90, day 270, and day 450.



RESULTS

- Primary efficacy endpoint: mean percent change in LDL-C at 510 days, was -56 in the inclisiran group compared with 1 in the placebo group ($p < 0.0001$); this was a time-averaged 56% reduction in LDL-C for inclisiran vs. placebo
- Exploratory cardiovascular endpoint: 7.4% with inclisiran vs. 10.2% with placebo

CONCLUSIONS

- Among patients with ASCVD on maximum tolerated statin therapy, twice yearly inclisiran injection resulted in a significant reduction in LDL-C; this was well tolerated with no sign of liver, muscle, or kidney toxicity

Presented by Dr. R. Scott Wright at AHA 2019